ImmunityBio, Inc. Net Income Loss

• ImmunityBio, Inc. showed an increase of +15.0% in Net Income Loss from 2024 to 2025.
• This data is from ImmunityBio, Inc.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
• XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 13 years of available data (2013 to 2025), ImmunityBio, Inc.'s Net Income Loss has declined by 17,066.5%.
• Historical annual values: Fiscal year 2025: -$351.40 million | Fiscal year 2024: -$413.56 million | Fiscal year 2023: -$583.20 million | Fiscal year 2022: -$416.57 million | Fiscal year 2021: -$346.79 million | Fiscal year 2020: -$221.85 million | Fiscal year 2019: -$157.78 million | Fiscal year 2018: -$96.23 million | Fiscal year 2017: -$96.42 million | Fiscal year 2016: -$120.81 million | Fiscal year 2015: -$236.88 million | Fiscal year 2014: -$6.19 million | Fiscal year 2013: -$2.05 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026